EDITORIAL
Autoimmune Pulmonary Alveolar Proteinosis: “The Sleeping Beauty and the Kissing Drug”
 
More details
Hide details
1
2nd Pulmonary Department, “Attikon” University Hospital, Athens Medical School, National and Kapodistrian University of Athens, Greece
 
2
2nd Department of Internal Medicine, “Attikon” General University Hospital, Medical School, University of Athens, Greece
 
3
7th Pulmonary Department and Asthma Center, Athens Chest Hospital, Greece
 
4
6th Pulmonary Department, Athens Chest Hospital, Greece
 
5
1st Pulmonary Department, Athens Chest Hospital, Athens Medical School, National and Kapodistrian University of Athens, Greece
 
6
Hauner Children’s University Hospital, Ludwig-Maximilians-University, Member of the German Center for Lung Research, Munich, Germany
 
 
Corresponding author
Spyros A. Papiris   

2nd Pulmonary Medicine Department, “Attikon” University Hospital, 1 Rimini Street, 12462, Haidari, Greece
 
 
Pneumon 2014;27(3):202-203
 
 
REFERENCES (17)
1.
Trapnell B, Whitsett J, Nakata K. Pulmonary alveolar proteinosis. N Engl J Med 2003;349:2527-39.
 
2.
Seymour JF, Presneill JJ. Pulmonary Alveolar Proteinosis. Progress in the first 44 years. Am J Respir Crit Care Med 2002;166:215-35.
 
3.
Trapnell BC, Carey BC, Uchida K, Suzuki T. Pulmonary alveolar proteinosis, a primary immunodeficiency of impaired GMCSF stimulation of macrophages. Curr Opin Immunol 2009;21:514-21.
 
4.
Dranoff G, Crawford AD, Sadelain M, et al. Involvement of granulocyte-macrophage colony stimulating factor in pulmonary homeostasis. Science 1994;264:713-6.
 
5.
Stanley E, Lieschke GJ, Grail D, et al. Granulocyte/macrophage colony stimulating factor deficient mice show no major perturbation of hemopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci USA 1994;91:5592-6.
 
6.
Kitamura T, Tanaka N, Watanabe J, et al. Idiopathic Pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte macrophage colony stimulating factor. J Exp Med 1999;190:875-80.
 
7.
Sakagami T, Uchida K, Suzuki T, et al. Human GM-CSF autoantibodies and reproduction of pulmonary alveolar proteinosis. N Engl J Med 2009;361:2679-81.
 
8.
Seymour JF, Dunn AR, Vincent JM, Presneill JJ, Pain MC. Efficacy of Granulocyte–Macrophage Colony- Stimulating Factor in acquired alveolar Proteinosis N Engl J Med 1996;335:1924-5.
 
9.
Kavuru MS, Sullivan EJ, Piccin R, Thomassen MJ, Stoller JK. Exogenous granulocyte-macrophage stimulating factor in acquired alveolar proteinosis. Am J Respir Crit Care Med 2000;161:1143-8.
 
10.
Seymour JF, Presneill JJ, Schoch OD, et al. Therapeutic efficacy of granulocyte-macrophage colony stimulating factor in patients with idiopathic acquired alveolar proteinosis. Am J Respir Crit Care Med 2001;163:524-31.
 
11.
Venkateshiah SB, Yan SB, Bonfield TL, et al. An open label trial of granulocyte-macrophage stimulating factor therapy for moderate symptomatic pulmonary alveolar proteinosis. Chest 2006;130:227-37.
 
12.
Wylam ME, Ten RM, Katzmann JA, Clawson M, Prakash UBS, Anderson PM. Aerosolized GM-CSF improves pulmonary function in idiopathic pulmonary alveolar proteinosis [abstract]. Am J Respir Crit Care Med 2000;161:A889.
 
13.
Wylam ME, Ten R, Prakash UBS, Nadrous HF, Clawson ML, Anderson PM. Aerosol granulocyte-macrophage colony-stimulating factor for pulmonary alveolar proteinosis. Eur Respir J 2006;27:585-93.
 
14.
Tazawa R, Trapnell BC, Inoue Y, et al. Inhaled granulocyte/macrophage colony stimulating factor as therapy for pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2010;181:1345-54.
 
15.
Griese M, Ripper J, Sibbersen A, et al. Long-term follow-up and treatment of congenital alveolar proteinosis. BMC Pediatr 2011;11:72.
 
16.
Beccaria M, Luisetti M, Rodi G, et al. Long-term durable benefit after whole lung lavage in pulmonary alveolar proteinosis. Eur Respir J 2004;23:526-31.
 
17.
Papiris SA, Tsirigotis P, Kolilekas L, et al. Long-term inhaled Granulocyte Macrophage-Colony Stimulating Factor in Autoimmune Pulmonary Alveolar Proteinosis: Effectiveness, safety, lowest-effective dose. Clin Drug Invest 2014;34:553-64.
 
eISSN:1791-4914
ISSN:1105-848X
Journals System - logo
Scroll to top